NEWS HIGHLIGHTSMedia Articles Related to Depocyt (Cytarabine)
Meningitis outbreak kills at least 40 in Guinea
Source: Yahoo! Health News [2013.04.30]
CONAKRY, Guinea (AP) — Health officials say a meningitis outbreak has killed at least 40 people in the West African nation of Guinea.
Deadly Meningitis Cases Worry Gay Community
Source: MedicineNet Encephalitis and Meningitis Specialty [2013.04.24]
Title: Deadly Meningitis Cases Worry Gay Community
Category: Health News
Created: 4/23/2013 12:35:00 PM
Last Editorial Review: 4/24/2013 12:00:00 AM
Childhood Meningitis Tied to Reduced Education, Employment Prospects
Source: MedicineNet Encephalitis and Meningitis Specialty [2013.04.24]
Title: Childhood Meningitis Tied to Reduced Education, Employment Prospects
Category: Health News
Created: 4/23/2013 4:35:00 PM
Last Editorial Review: 4/24/2013 12:00:00 AM
Combo Therapy Helps Knock Out Fungal Meningitis
Source: MedicineNet Encephalitis and Meningitis Specialty [2013.04.04]
Title: Combo Therapy Helps Knock Out Fungal Meningitis
Category: Health News
Created: 4/3/2013 6:35:00 PM
Last Editorial Review: 4/4/2013 12:00:00 AM
FDA, States Weigh Pharmacy Regulation in Wake of Meningitis Outbreak
Source: MedicineNet Cortisone Injection Specialty [2012.12.21]
Title: FDA, States Weigh Pharmacy Regulation in Wake of Meningitis Outbreak
Category: Health News
Created: 12/20/2012 12:36:00 PM
Last Editorial Review: 12/21/2012 12:00:00 AM
Published Studies Related to Depocyt (Cytarabine)
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. [2011.08.18]
To assess the value of administering timed-sequential chemotherapy (TSC; 2 therapeutic sequences separated by a 4-day interval-free chemotherapy) or high-dose cytarabine (HDAraC) cycles in consolidation therapy for acute myeloid leukemia (AML), 459 patients 15 to 50 years of age were enrolled in the prospective randomized Acute Leukemia French Association-9802 trial...
Cytarabine dose of 36 g/m(2) compared with 12 g/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. [2011.07.01]
PURPOSE: To assess the optimal cumulative dose of cytarabine for treatment of young adults with acute myeloid leukemia (AML) within a prospective multicenter treatment trial... CONCLUSION: In young adults with AML receiving intermediate-dose cytarabine induction, intensification of the cytarabine dose beyond 12 g/m(2) within first consolidation did not improve treatment outcome.
Cytarabine dose for acute myeloid leukemia. [2011.03.17]
BACKGROUND: Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the conventional dose of 100 to 400 mg per square meter. Intermediate dose levels have not been thoroughly evaluated... CONCLUSIONS: Induction therapy with cytarabine at the lower dose already produced maximal antileukemic effects for all response end points, suggesting a plateau in the dose-response relationship above this dose level. High-dose cytarabine results in excessive toxic effects without therapeutic benefit. (Netherlands Trial Register number, NTR230.).
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. [2011.02.24]
We conducted a prospective randomized study to assess the optimal postremission therapy for adult acute myeloid leukemia in patients younger than 65 years in the first complete remission. A total of 781 patients in complete remission were randomly assigned to receive consolidation chemotherapy of either 3 courses of high-dose cytarabine (HiDAC, 2 g/m(2) twice daily for 5 days) alone or 4 courses of conventional standard-dose multiagent chemotherapy (CT) established in the previous JALSG AML97 study...
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. [2010.03]
A multicenter, prospective, randomized study was conducted to compare a response-oriented individualized remission induction therapy with a standard fixed-schedule induction therapy, using idarubicin (IDR) and cytarabine (Ara-C), in adult patients with acute myeloid leukemia (AML)...
Clinical Trials Related to Depocyt (Cytarabine)
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma [Recruiting]
Current treatments for Glioblastoma Multiforme (GBM), the most common and malignant primary
brain tumor are inadequate and as such, the median survival for most patients with GBM is on
the order of months, even after cytoreductive surgery, radiation and chemotherapy. This
study aims to develop a new treatment for GBM by suppressing glial progenitor cells that
surround the ventricular system in patients with these aggressive tumors because it is these
regions that appear to act as an incubator for future recurrences resulting in patient
death. Considering the lack of significant treatment options for patients with this
uniformly fatal disease, this is an important translational clinical study to perform.
High-dose Methotrexate and Liposomal Cytarabine in Treating Patients With CNS Metastases From Breast Cancer [Recruiting]
This phase II trial is studying how well giving high-dose methotrexate together with
liposomal cytarabine works in treating patients with central nervous system (CNS) metastases
from metastatic breast cancer. Drugs used in chemotherapy, such as methotrexate and
liposomal cytarabine, work in different ways to stop the growth of cancer cells, either by
killing the cells or by stopping them from dividing. Giving high-dose systemic methotrexate
with intra-cerebral spinal fluid (CSF) liposomal cytarabine may kill more tumor cells
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis. [Not yet recruiting]
The purpose of this study is to demonstrate the safety of giving Whole Brain Radiotherapy
(WBRT) together with intrathecal liposomal cytarabine (DepoCyte®) for patients with
leptomeningeal metastases. The study will compare the safety of giving DepoCyte at the same
time as WBRT with giving the drug after WBRT is complete.
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma [Recruiting]
Current treatments for Glioblastoma Multiforme (GBM), the most common and malignant primary
brain tumor are inadequate and as such, the median survival for most patients with GBM is on
the order of months, even after cytoreductive surgery, radiation and chemotherapy. This
study aims to develop a new treatment for GBM by suppressing glial progenitor cells that
surround the ventricular system in patients with these aggressive tumors because it is these
regions that appear to act as an incubator for future recurrences resulting in patient
death. Considering the lack of significant treatment options for patients with this
uniformly fatal disease, this is an important translational clinical study to perform.
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL) [Recruiting]
Several groups, especially the PETHEMA group (in their LPA96 and 99 trials), obtained low
relapse rates in newly diagnosed Acute Promyelocytic Leukemia (APL) patients by combining
ll-transretinoic acid (ATRA) and anthracyclines without Ara-C, suggesting that avoiding
Ara-C in the chemotherapy of APL reduced treatment toxicity without increasing relapses.
While the relapse rate for the children with white blood cell(WBC) counts greater than
10×109/L at presentation were higher than those WBC counts less than 10×109/L (31% and
3. 5%,respectively) in the LPA96 and 99 trials. A recent adult randomized trial show that
avoiding Ara-C leads to an increased risk of relapse in the APL patients with WBC counts
less than 10×109/L. The role of the Ara-C remains controversial. And there are very limited
data reported on children with APL so far.
Reports of Suspected Depocyt (Cytarabine) Side Effects
Headache (9),
Mucosal Inflammation (7),
Arachnoiditis (6),
Coma (6),
Hepatic Enzyme Increased (6),
Hyperkalaemia (5),
Deafness (5),
Pneumocystis Jiroveci Pneumonia (5),
Herpes Simplex (5),
Dysarthria (5), more >>
|
